Sigilon Therapeutics Long Term Debt

Sigilon Therapeutics (SGTX) currently reports a long-term debt of $2.9M as of June 2023. That compares with $22M in the prior-year period — down 87.0% year over year. Use the charts on this page to explore Sigilon Therapeutics's long-term debt history and peer comparisons.

Sigilon Therapeutics's long-term debt decreased from $22M to $2.9M — a 87.0% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sigilon Therapeutics reported $2.9M in long-term debt as of June 2023. That compares with $22M in the prior-year period — down 87.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $2.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.

Sigilon Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $2.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGTX with unrelated industries.